Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06163469 · ClinicalTrials.gov registry record · NA
Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life
A NA study of Neurogenic Bladder and Urinary Retention, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06163469 is a NA study of Neurogenic Bladder and Urinary Retention that is actively recruiting participants, run by Yale University. The registered enrollment target is 70 participants, below the 89-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06163469, a NA study of Neurogenic Bladder and Urinary Retention, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate the feasibility and tolerability of 0.05% Chlorhexidine Gluconate (CGH) bladder instillations in an outpatient setting at the time of suprapubic catheter (SPC) exchange in patients with history of recurrent urinary tract infections (UTI). The main questions are: 1. is instillation of 150mL of CGH for five-minute duration at the time of SPC exchange feasible in an outpatient setting and tolerable for patients. 2. does this protocol decrease the rate of unplanned health care visits and improve patient quality of life. Patients will undergo the treatment protocol during their routine suprapubic catheter exchanges.
Conditions Studied
Interventions
- DEVICE Bladder instillation with Irrisept
Study Locations (1)
Connecticut
- Yale New Haven Health - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06163469
The ClinicalTrials.gov registry entry for NCT06163469 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 16 other Neurogenic Bladder trials with a reported enrollment target (21% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neurogenic Bladder appearing as the primary indexed condition, and to 1 intervention - of which Bladder instillation with Irrisept is the first listed.
NCT06163469 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06163469 about?
NCT06163469 is a clinical study titled "Effect of Chlorhexidine Gluconate Bladder Instillations in Patients With Chronic Suprapubic Catheters on Unplanned Healthcare Encounters and Quality of Life". The goal of this clinical trial is to evaluate the feasibility and tolerability of 0.05% Chlorhexidine Gluconate (CGH) bladder instillations in an outpatient setting at the time of suprapubic catheter (SPC) exchange in patients with history of recurrent urinary tract infections (UTI). The main quest...
What is the current status of trial NCT06163469?
This trial is currently recruiting. It is a NA study. The enrollment target is 70 participants. The study started on 2024-04-01. Estimated completion is 2025-12-31.
What conditions does trial NCT06163469 study?
This clinical trial studies the following conditions: Neurogenic Bladder, Urinary Retention.
What interventions are being tested in trial NCT06163469?
The interventions under investigation include: Bladder instillation with Irrisept (DEVICE).
Who is sponsoring clinical trial NCT06163469?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06163469 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurogenic Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
RECRUITING · NA
-
Vascularized Composite Bladder Allograft Transplantation
RECRUITING · NA
-
Electrical Stimulation for Continence After Spinal Cord Injury
ACTIVE NOT RECRUITING · NA
-
Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation
COMPLETED · NA
-
Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE "CONTINENCE" Clinical Study
COMPLETED · NA
-
Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.